Clinical Trial Update: InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression [Phase 3]

View source ↗

Summary

Phase 3 trial update for intravenous ketamine combined with immersive virtual reality to treat treatment-resistant depression; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Treatment-resistant Depression

Drugs mentioned

• Ketamine (ketamine)

Snippet

Sponsor: Sunnybrook Health Sciences Centre | Conditions: Treatment Resistant Depression | Phase 3 | Status: NOT_YET_RECRUITING